It appears that FDA previous comments were not addressed for some reasons or another. SNTS should have known better. WOW, another CEO and MGMT, a sleep at the wheel. At this moment, I am so disappointed with this shxx.
In the holehttp://www.businesswire.com/news/home/20110227005080/en/Santarus-Pharming-Announce-Receipt-FDA-Refusal-File
Plenty of cash on hand, product in the market and excellect pipeline.Analysis target $8 ps
I'm happy for this silence. When people will arrive there will be a lot of confusion and will be too late to buy.
http://files.shareholder.com/downloads/SNTS/1125193493x0x434008/7d2e581d-2c08-4586-a79e-33d64c6b13fd/Investor%20Meetings%201-10-11%20to%201-12-11.pdfslide 14http://www.chasingthealpha.com/p/fda-decisions-and-trials.htmlMonday could be hot!!!Why is there this desert?
BSR initiates SNTS coverage in their Feb. issue .... given BSR's track record ... you may want to chalk that up under the 'good' column.
Santarus has so many products in the pipeline.Excellent information, We are now waiting for Monday's uptick, profits on Mar 3 and more good future news.Thank you,Buck